Lexaria Bioscience (LEXX) Stock Price, News & Analysis

Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Key Stats

• Today's Range: $1.23 to $1.45
• 50-Day Range: $1.21 to $1.82
• 52-Week Range: $1.15 to $4.44
• Volume: 600,311 shs
• Average Volume: 171,179 shs
• Market Capitalization: $23.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Lexaria Bioscience Stock Analysis - MarketRank™

Lexaria Bioscience scored higher than 53% of companies evaluated by MarketBeat, and ranked 435th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lexaria Bioscience has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.59) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexaria Bioscience is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexaria Bioscience is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexaria Bioscience has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.20% of the float of Lexaria Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Lexaria Bioscience has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Lexaria Bioscience has recently decreased by 23.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexaria Bioscience does not currently pay a dividend.

Dividend Growth

Lexaria Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.20% of the float of Lexaria Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Lexaria Bioscience has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Lexaria Bioscience has recently decreased by 23.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.58

News Sentiment

Lexaria Bioscience has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.40% of the stock of Lexaria Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.06% of the stock of Lexaria Bioscience is held by institutions.

LEXX Stock Analysis - Frequently Asked Questions

How have LEXX shares performed this year?

Lexaria Bioscience's stock was trading at $2.10 at the start of the year. Since then, LEXX shares have decreased by 35.7% and is now trading at $1.35.
View the best growth stocks for 2025 here.

How were Lexaria Bioscience's earnings last quarter?

Lexaria Bioscience Corp. (NASDAQ:LEXX) posted its quarterly earnings results on Monday, April, 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company earned $0.17 million during the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative trailing twelve-month return on equity of 88.88% and a negative net margin of 1,473.04%.

Who are Lexaria Bioscience's major shareholders?

Lexaria Bioscience's top institutional shareholders include Byrne Asset Management LLC (0.16%). Insiders that own company stock include Richard Christopher, Catherine C Turkel and Vanessa Carle.
View institutional ownership trends.

How do I buy shares of Lexaria Bioscience?

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR).

Company Calendar

• Last Earnings: 4/14/2025
• Today: 4/27/2025
• Next Earnings (Estimated): 7/11/2025
• Fiscal Year End: 8/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LEXX
• CIK: 1348362
• Web: www.lexariabioscience.com
• Phone: (250) 765-6424
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +418.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,800,000.00
• Net Margins: -1,473.04%
• Pretax Margin: -1,475.05%
• Return on Equity: -88.88%
• Return on Assets: -83.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.62
• Quick Ratio: 29.62

Sales & Book Value

• Annual Sales: $525,923.00
• Price / Sales: 45.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 17,559,000
• Free Float: 12,919,000
• Market Cap: $23.70 million
• Optionable: Not Optionable
• Beta: 0.86